CISPLATIN


Trade Names	CISPLATIN PLATINOL PLATINOL-AQ
Synonyms	CIS-DDP Cis-diamminedichloroplatinum Cis-diamminedichloroplatinum ii Cis-platin Cis-platinum ii Cisplatin Cisplatinum Fauldiscipla INT-230-6 COMPONENT CISPLATIN INT230-6 COMPONENT CISPLATIN Liplacis NSC-119875 Peyrone's salt Platinol Platinol-aq cis-diamminedichloroplatinum(II)
Status
Molecule Category	UNKNOWN
ATC	L01XA01
UNII	Q20Q21Q62J


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Physicochemical Descriptors

Property Name	Value
Molecular Formula	H6Cl2N2Pt+2
Molecular Weight	300.05
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Bioactivity

Mechanism of Action	Action	Reference
DNA inhibitor	INHIBITOR	FDA ISBN

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group A Nuclear hormone receptor subfamily 3 group A member 1	-	2500-10300	-	-	-
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group A Nuclear hormone receptor subfamily 3 group A member 2	-	2500-10300	-	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	109

Cross References

Resources	Reference
ChEMBL	CHEMBL11359
DrugBank	DB00515
FDA SRS	Q20Q21Q62J
Guide to Pharmacology	5343
PDB	NCP
PubChem	84691
ChEMBL	CHEMBL2068237
DrugBank	DB00515
FDA SRS	Q20Q21Q62J
Guide to Pharmacology	5343
PDB	NCP
PubChem	84691

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).